Trinity Biotech (NASDAQ:TRIB) released its earnings results on Tuesday. The company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.07 by ($0.26), Morningstar.com reports. The business had revenue of $22.50 million during the quarter. Trinity Biotech had a positive return on equity of 3.20% and a negative net margin of 23.81%.
NASDAQ:TRIB opened at $1.44 on Wednesday. The firm’s 50-day moving average price is $2.05 and its 200-day moving average price is $2.43. The company has a market capitalization of $40.87 million, a PE ratio of 14.17 and a beta of 1.38. The company has a debt-to-equity ratio of 1.86, a current ratio of 4.30 and a quick ratio of 2.74. Trinity Biotech has a 1-year low of $1.44 and a 1-year high of $4.37.
Several large investors have recently added to or reduced their stakes in TRIB. BlackRock Inc. purchased a new position in Trinity Biotech during the 4th quarter valued at $141,000. Lapides Asset Management LLC grew its position in Trinity Biotech by 2.1% during the 1st quarter. Lapides Asset Management LLC now owns 655,600 shares of the company’s stock valued at $1,868,000 after purchasing an additional 13,700 shares during the last quarter. Hunter Associates Investment Management LLC grew its position in Trinity Biotech by 10.8% during the 1st quarter. Hunter Associates Investment Management LLC now owns 1,078,610 shares of the company’s stock valued at $3,074,000 after purchasing an additional 104,928 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Trinity Biotech by 11.7% during the 2nd quarter. Renaissance Technologies LLC now owns 685,496 shares of the company’s stock valued at $1,131,000 after acquiring an additional 71,685 shares during the period. 51.16% of the stock is currently owned by hedge funds and other institutional investors.
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes.
Read More: What is meant by holder of record?
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.